{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:27:34Z","timestamp":1753892854963,"version":"3.41.2"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Novel Coronary Pneumonia is the most infectious disease with the highest number of morbidity and mortality in 100 years. Despite aggressive and effective COVID-19 prevention and control measures, countries have been unable to stop its outbreaks. With the widespread use of vaccines, the occurrence of COVID-19 has declined markedly. April 21, 2021, New York scholars reported Vaccine Breakthrough Infections with SARS-CoV-2 Variants, which immediately attracted widespread attention. In this mini-review, we focus on the characteristics of SARS-CoV-2 and its mutant strains and vaccine breakthrough infections. We have found that outbreaks of vaccine-breaking SARS-CoV-2 Delta infections in many countries are primarily the result of declining vaccine-generated antibody titers and relaxed outbreak management measures. For this reason, we believe that the main response to vaccine-breaking infections with the SARS-CoV-2 variant is to implement a rigorous outbreak defense policy and vaccine application. Only by intensifying the current vaccination intensity, gradually improving the vaccine and its application methods, and strengthening non-pharmaceutical measures such as travel restrictions, social distancing, masking and hand hygiene, can the COVID-19 outbreak be fully controlled at an early date.<\/jats:p>","DOI":"10.3389\/fpubh.2022.842303","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T08:18:54Z","timestamp":1647332334000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["How to Deal With Vaccine Breakthrough Infection With SARS-CoV-2 Variants"],"prefix":"10.3389","volume":"10","author":[{"given":"Ying","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caide","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guosheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiliang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajic.2020.11.018","article-title":"Willingness to get the COVID-19 vaccine with and without emergency use authorization","volume":"49","author":"Guidry","year":"2021","journal-title":"Am J Infect Control."},{"key":"B5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/v13010054","article-title":"Lead SARS-CoV-2 candidate vaccines: expectations from phase III trials and recommendations post-vaccine approval","volume":"13","author":"Tumban","year":"2020","journal-title":"Viruses."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.4103\/ijph.IJPH_520_20","article-title":"COVID-19 vaccine development and the way forward","volume":"64","author":"Arora","year":"2020","journal-title":"Indian J Public Health."},{"key":"B7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijid.2021.09.022","article-title":"Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain","volume":"112","author":"Barandalla","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2100626","DOI":"10.2807\/1560-7917.ES.2021.26.27.2100626","article-title":"An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021.","volume":"26","author":"Williams","year":"2021","journal-title":"Euro Surveill"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.15585\/mmwr.mm7035e2","article-title":"Outbreak associated with SARS-CoV-2 B.1.617.2 (Delta) variant in an elementary school - Marin County, California, May-June 2021","volume":"70","author":"Lam-Hine","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.15585\/mmwr.mm7038e3","article-title":"Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant infections among incarcerated persons in a Federal Prison - Texas, July-August 2021","volume":"70","author":"Hagan","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.15585\/mmwr.mm7032e2","article-title":"Rapid increase in circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant - Mesa County, Colorado, April-June 2021","volume":"70","author":"Herlihy","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2100573","DOI":"10.2807\/1560-7917.ES.2021.26.28.2100573","article-title":"Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021","volume":"26","author":"Alizon","year":"2021","journal-title":"Euro Surveill."},{"key":"B13","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.1039\/D1NR01672E","article-title":"Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study","volume":"13","author":"Yang","year":"2021","journal-title":"Nanoscale."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/v13081498","article-title":"Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection","volume":"13","author":"Halwe","year":"2021","journal-title":"Viruses."},{"key":"B15","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1101\/2020.09.10.286948","article-title":"Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles","volume":"28","author":"Lu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1101\/2020.05.28.121533","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife."},{"key":"B18","doi-asserted-by":"publisher","first-page":"141486","DOI":"10.1016\/j.scitotenv.2020.141486","article-title":"Understanding air and water borne transmission and survival of coronavirus: insights and way forward for SARS-CoV-2","volume":"749","author":"Wathore","year":"2020","journal-title":"Sci Total Environ."},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/irv.12682","article-title":"Effects of temperature, humidity, and diurnal temperature range on influenza incidence in a temperate region","volume":"14","author":"Park","year":"2020","journal-title":"Influenza Other Respir Viruses."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.12998\/wjcc.v8.i8.1391","article-title":"Stability and infectivity of coronaviruses in inanimate environments","volume":"8","author":"Ren","year":"2020","journal-title":"World J Clin Cases."},{"key":"B21","doi-asserted-by":"publisher","first-page":"evab196","DOI":"10.1093\/gbe\/evab196","article-title":"Causes and Consequences of purifying selection on SARS-CoV-2","volume":"13","author":"Morales","year":"2021","journal-title":"Genome Biol Evol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41564-021-00932-w","article-title":"SARS-CoV-2 variants of interest and concern naming scheme conducive for global discourse","volume":"6","author":"Konings","year":"2021","journal-title":"Nat Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"101129","DOI":"10.1016\/j.eclinm.2021.101129","article-title":"Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China","volume":"40","author":"Wang","year":"2021","journal-title":"EClinicalMedicine."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3201\/eid2712.211792","article-title":"Breakthrough infections of E484K-harboring SARS-CoV-2 Delta variant, Lombardy, Italy","volume":"27","author":"Baj","year":"2021","journal-title":"Emerg Infect Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12916-021-02103-4","article-title":"Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections","volume":"19","author":"Farinholt","year":"2021","journal-title":"BMC Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41577-020-00451-5","article-title":"COVID-19 herd immunity: where are we?","volume":"20","author":"Fontanet","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"25897","DOI":"10.1073\/pnas.2008087117","article-title":"Transmission dynamics reveal the impracticality of COVID-19 herd immunity strategies","volume":"117","author":"Brett","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S2542-5196(20)30170-4","article-title":"COVID-19 and heatwaves: a double whammy for Indian cities","volume":"4","author":"Golechha","year":"2020","journal-title":"Lancet Planet Health."},{"key":"B30","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1126\/science.373.6557.838","article-title":"Israel's grim warning: delta can overwhelm shots","volume":"373","author":"Wadman","year":"2021","journal-title":"Science."},{"key":"B31","doi-asserted-by":"publisher","first-page":"108814","DOI":"10.1016\/j.clim.2021.108814","article-title":"Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection","volume":"230","author":"Dehgani-Mobaraki","year":"2021","journal-title":"Clin Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12879-021-06156-x","article-title":"do Amaral IPC, et al. Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population","volume":"21","author":"Bichara","year":"2021","journal-title":"BMC Infect Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"107893","DOI":"10.1016\/j.intimp.2021.107893","article-title":"Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: a prospective longitudinal cohort study","volume":"98","author":"Moradi","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.15585\/mmwr.mm7034e4","article-title":"Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B","volume":"70","author":"Fowlkes","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3390\/v13091782","article-title":"Clinical characterization and genomic analysis of samples from COVID-19 breakthrough infections during the second wave among the various states of India","volume":"13","author":"Gupta","year":"2021","journal-title":"Viruses"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.15585\/mmwr.mm7028e2","article-title":"SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility - Oklahoma, April-May 2021","volume":"70","author":"Dougherty","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.15585\/mmwr.mm7034e5","article-title":"SARS-CoV-2 infections and hospitalizations among persons aged \u226516 years, by vaccination status - Los Angeles County, California, May 1-July 25, 2021","volume":"70","author":"Griffin","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jinf.2021.08.006","article-title":"Predominance of delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021","volume":"84","author":"Thangaraj","year":"2021","journal-title":"J Infect."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2100824","DOI":"10.2807\/1560-7917.ES.2021.26.37.2100824","article-title":"Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021","volume":"26","author":"Blanquart","year":"2021","journal-title":"Euro Surveill."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2100822","DOI":"10.2807\/1560-7917.ES.2021.26.39.2100822","article-title":"Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021","volume":"26","author":"Shitrit","year":"2021","journal-title":"Euro Surveill"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/infdis\/jiab410","article-title":"Severe acute respiratory syndrome coronavirus 2 variant delta infects all 6 siblings but spares comirnaty (BNT162b2, BioNTech\/Pfizer)-vaccinated parents","volume":"224","author":"Nathan","year":"2021","journal-title":"J Infect Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1056\/NEJMc2107808","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"385","author":"Rana","year":"2021","journal-title":"N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","article-title":"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact","volume":"22","author":"Lipsitch","year":"2022","journal-title":"Nat Rev Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jama.2021.22898","article-title":"Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection","volume":"327","author":"Bates","year":"2022","journal-title":"JAMA."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"eabh1823","DOI":"10.1126\/science.abh1823","article-title":"Cross-reactive CD4 T cells enhance SARS-CoV-2 immune responses upon infection and vaccination","volume":"374","author":"Loyal","year":"2021","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med."},{"key":"B50","unstructured":"2022"},{"key":"B51","doi-asserted-by":"publisher","first-page":"690621","DOI":"10.3389\/fcimb.2021.690621","article-title":"COVID-19 pandemic and vaccines update on challenges and resolutions","volume":"11","author":"Khan","year":"2021","journal-title":"Front Cell Infect Microbiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2468-2667(21)00031-1","article-title":"Migrant health is public health: a call for equitable access to COVID-19 vaccines","volume":"6","author":"Al-Oraibi","year":"2021","journal-title":"Lancet Public Health."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.1c00557","article-title":"Emerging vaccine-breakthrough SARS-CoV-2 variants","author":"Wang","year":"2021"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-021-01413-7","article-title":"Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals","volume":"27","author":"Kustin","year":"2021","journal-title":"Nat Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.chom.2021.02.019","article-title":"Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies","volume":"29","author":"Zhou","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O'Brien","year":"2021","journal-title":"N Engl J Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"863","DOI":"10.46234\/ccdcw2021.213","article-title":"Eleven COVID-19 outbreaks with local transmissions caused by the imported SARS-CoV-2 Delta VOC - China, July-August, 2021","volume":"3","author":"Zhou","year":"2021","journal-title":"China CDC Wkly."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.3346\/jkms.2021.36.e14","article-title":"Symptoms and characteristics which require attention during COVID-19 screening at a port of entry","volume":"36","author":"Song","year":"2021","journal-title":"J Korean Med Sci."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.842303\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T08:18:57Z","timestamp":1647332337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.842303\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":61,"alternative-id":["10.3389\/fpubh.2022.842303"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.842303","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"article-number":"842303"}}